Danish drugmaker Novo Nordisk expects sales of its diabetes medications Ozempic and Wegovy to surge by 16-24% this year, driven by increased demand and supply chain challenges. The company cited periodic supply constraints as a major factor in its forecast, with revenue growth rates similar to those seen last year. Following the announcement, Novo Nordisk’s shares rose 6.3% in Copenhagen trading, indicating investor confidence in the company’s future performance.
Source: https://www.bloomberg.com/news/articles/2025-02-05/novo-sees-sales-growth-slowing-amid-supply-constraints